The information contained in the website is solely intended for professional investors. Some funds shown on this website fall outside the scope of the Dutch Act on the Financial Supervision (Wet op het financieel toezicht) and therefore do not (need to) have a license from the Authority for the Financial Markets (AFM).
The funds shown on this website may not be available in your country. Please select your country website (top right corner) to view the products that are available in your country.
Neither information nor any opinion expressed on the website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, annual and semi-annual reports, which can be all be obtained free of charge at this website and at the Robeco offices in each country where Robeco has a presence.
One oft-heard concern on factor investing is that factors could be arbitraged away. Indeed, studies on the US equity market suggest that market anomalies become weaker after publication, with performance deteriorating by over 50%.
This study1, however, found that these results do not carry over to international equity markets. The authors examined over 200 anomalies for 39 countries and found that only the US exhibited a post-publication performance drop. None of the other countries showed noticeable decline in performance, or even a slight improvement. The authors considered the various explanations for these conflicting results.
They dismissed most of these, but found weak evidence supporting the notion that anomalies are more difficult to arbitrage away internationally. We suggest a different explanation, namely that most anomaly studies focus on the US market and have been optimized to produce the best results there. Such data fitting would explain why subsequent performance is weaker in the US market, but not in other markets where the strategies were not initially tested.
1 Jacobs & Müller, ‘Anomalies Across the Globe: Once Public, No Longer Existent?’, SSRN working paper, no. 2816490, 201.